This study validated an automated, scalable comprehensive genomic profiling assay this with an expanded gene panel of 141 genes in 293 patients with hematologic malignancies for the detection of clinically informative genomic alterations.
AACR 2024 -- Monoclonal antibodies (mAbs) that target tumor antigen have transformed cancer immunotherapy. Antibody-dependent cellular cytotoxicity (ADCC) is an indispensable therapeutic mechanism for mAbs, including antibody-drug conjugates, because they trigger immune-mediated antitumor activity in vivo.
AACR 2024 -- Traditional cancer cell lines used as surrogate models in vitro and in vivo have made significant contributions to cancer research and drug discovery.
AACR 2024 -- The failure of murine tumor models to adequately simulate the native biological milieu and tissue architecture of human malignancies, has fomented much discourse surrounding the exigencies of bench to bedside translation.
AACR 2024 -- The tumor microenvironment consists of various components such as cancer-associated fibroblasts, immune cells, blood vessels and extracellular matrix elements, all of which have the potential to interact with cancer cells.
AACR 2024 -- Immunotherapy aims to bolster the immune response within the tumor microenvironment (TME). However, checkpoint inhibitors utilized in the treatment of colon carcinoma have demonstrated efficacy only in certain patients.
Labcorp acquires Baystate Health’s outreach laboratory business and select operating assetsCollaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts
This graphical summary provides a quick look at recently published manuscript - The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
